These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 14672509

  • 21. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis.
    Shimizu H, Kataoka H, Kawahara M, Hirano M, Furiya Y, Ueno S.
    Clin Neurol Neurosurg; 2007 Apr; 109(3):277-8. PubMed ID: 17118531
    [Abstract] [Full Text] [Related]

  • 22. Concurrence of multiple sclerosis and primary intracranial neoplasms.
    Ho KL, Wolfe DE.
    Cancer; 1981 Jun 15; 47(12):2913-9. PubMed ID: 7260877
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 24. Co-occurrence of multiple sclerosis and glioma--case report and neuropathologic and epidemiologic review.
    Malmgren RM, Detels R, Verity MA.
    Clin Neuropathol; 1984 Jun 09; 3(1):1-9. PubMed ID: 6323082
    [Abstract] [Full Text] [Related]

  • 25. [Treatment with beta-interferon should be started already after the first attack of MS].
    Söderström M.
    Lakartidningen; 2001 Feb 07; 98(6):587-90, 593-4. PubMed ID: 11475246
    [No Abstract] [Full Text] [Related]

  • 26. A 52-year-old man with progressive left-sided weakness and white matter disease.
    Fleming JO, Keegan BM, Parisi JE.
    Neurology; 2007 Aug 07; 69(6):600-6. PubMed ID: 17679680
    [No Abstract] [Full Text] [Related]

  • 27. Palpitations: could they be neurogenic? A case report.
    Gandelman-Marton R, Segev Y, Theitler J, Rabey JM, Pollak L.
    Neurologist; 2006 May 07; 12(3):160-2. PubMed ID: 16688017
    [Abstract] [Full Text] [Related]

  • 28. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G.
    Clin Ther; 2009 Jun 07; 31(6):1142-57. PubMed ID: 19695384
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis.
    Montero JA, Sanchis ME, Fernandez-Munoz M.
    J Neuroophthalmol; 2007 Mar 07; 27(1):36-40. PubMed ID: 17414871
    [Abstract] [Full Text] [Related]

  • 32. Multiple sclerosis preceding CNS lymphoma: a case report.
    Yang JH, Wu SL.
    Acta Neurol Taiwan; 2007 Jun 07; 16(2):92-7. PubMed ID: 17685133
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report.
    Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M.
    Neuro Endocrinol Lett; 2008 Dec 07; 29(6):867-70. PubMed ID: 19112415
    [Abstract] [Full Text] [Related]

  • 35. [Coincidence of juvenile idiopathic arthritis and multiple sclerosis: case report].
    Puszczewicz MJ, Tuchocka-Piotrowska A, Majewski D, Kołczewska A.
    Ann Acad Med Stetin; 2006 Dec 07; 52 Suppl 2():85-8. PubMed ID: 17471842
    [Abstract] [Full Text] [Related]

  • 36. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
    Bagnato F, Gupta S, Richert ND, Stone RD, Ohayon JM, Frank JA, McFarland HF.
    Arch Neurol; 2005 Nov 07; 62(11):1684-8. PubMed ID: 16157739
    [Abstract] [Full Text] [Related]

  • 37. Fatal tumor hemorrhage after ventriculoperitoneal shunting. Case report.
    Schroeder HW, Niendorf WR, Schwesinger G, Gaab MR.
    Neuropediatrics; 1995 Jun 07; 26(3):177-9. PubMed ID: 7477758
    [Abstract] [Full Text] [Related]

  • 38. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S, Vardi J, Finkelstein Y, Pollak L.
    Isr Med Assoc J; 2007 Jun 07; 9(6):457-9. PubMed ID: 17642394
    [Abstract] [Full Text] [Related]

  • 39. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group.
    Arch Neurol; 2005 May 07; 62(5):785-92. PubMed ID: 15883267
    [Abstract] [Full Text] [Related]

  • 40. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N, Kraus J, Bauer R, Engelhardt B, Bregenzer T, Kuehne BS, Tofighi J, Laske C, Stolz E, Blaes F, Voigt K, Traupe H, Kaps M, Oschmann P.
    Acta Neurol Scand; 2004 Dec 07; 110(6):377-85. PubMed ID: 15527450
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.